In an article published on AJMC.com, IVI'sJennifer Bright and Mark Linthicum argue value assessment stakeholders need to have transparent discussions about value assessment and understand what value means from other points of view. Read the full article here.
Precision Benefit Design: How should the arrival of precision medicine affect health plan benefit design?
Advances in precision medicine offer the promise of tremendous gains in patient health over the coming decades. Headlines in the popular press as well as discussions at academic conferences tout the potential benefits of precision medicine, while at the same time critiquing the nascent but growing evidence base and the high cost of treatment. One [...]
While it makes sense for value assessment to be woven into healthcare decision making, relying on a single method to measure value and using this metric to restrict treatment access is shortsighted. IVI's Jennifer Bright and Mark Linthicum address this concern in a recent article for the American Journal of Managed Care (AJMC). Read the [...]
There isn't an easy answer to assessing value in healthcare, but IVI is working to tackle the problems through considerable research and experimentation by developing an open-source value platform that considers no only clinical factors, but patient perspectives as well. In a recent interview with PatientEngagementHIT.com, IVI's Jennifer Bright (Executive Director) and Mark Linthicum (Director [...]
IVI Provides Insight into CVS Health’s Decision to Include Cost-per-QALY Analyses from ICER into Formulary Decision-Making
CVS Health's pharmacy benefit management (PBM) division, CVS Caremark, recently announced their decision to rely exclusively on the analyses of the Institute for Clinical and Economic (ICER) in a new drug management program. IVI's Director of Scientific Communications, Mark Linthicum, responds to this story in MedCity stating, "The neat 'answer' regarding the value of treatment [...]
In an op-ed published in Healthcare Business News, IVI's Executive Director, Jennifer Bright, describes four essential steps necessary to better measure value in healthcare: Better value measurement must incorporate the patient perspective into all assessment tools. Real world data must be considered when determining a treatment's worth beyond direct clinical benefit. Value assessments must be [...]
In an op-ed published by Fierce Healthcare, Director of Scientific Communications, Mark Linthicum discusses current shortfalls of value assessment and what is needed to move to value assessment 2.0. Read the full article here.
Measuring value in healthcare, which frequently takes the perspective of a single payer managing population health and costs, needs to evolve to include diverse perspectives and provide relevant and actionable information on value to healthcare decision makers, according to a new article written by IVI’s Mark Linthicum, Jennifer Bright and Jason Shafrin and published [...]
In a post on the IVI-sponsored Health Affairs featured blog series, Drugs and Medical Innovation, Jason Shafrin (IVI Director of Research) and Mark Linthicum (IVI Director of Scientific Communications) explore the role that formularies play in determining value for different stakeholders, and how unique, multi-stakeholder efforts can make formularies more patient-centered. Read the full article [...]
In a post on the IVI-sponsored Health Affairs featured blog series Drugs and Medical Innovation, Daniel Blumenthal, Samuel Nussbaum (IVI Strategic Advisory Panel Chair), Mark Linthicum (IVI Director of Scientific Communications), and Neil Weissman (IVI Strategic Advisory Panel member) explore how outcomes-based pricing agreements (OBAs) could be utilized for medical devices used to treat cardiovascular [...]